Insulin-like growth factors and prostate cancer

Epidemiologic Reviews

Volumn 23, Issue 1, 2001, Pages 59-66

  Pollak, M ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN;

CANCER RISK; CANCER SCREENING; CORRELATION FUNCTION; HORMONE BLOOD LEVEL; HORMONE METABOLISM; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

EID: 0034806357     PISSN: 0193936X     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.epirev.a000796     Document Type: Review

References (67)

1. Insulin-like growth factor physiology and cancer risk
2. Insulin-like growth factors and prostate cancer
3. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth
4. Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3
5. Nutritional regulation of the insulin-like growth factors
6. Normal growth and development in the absence of hepatic insulin-like growth factor I
7. Insulin-like growth factors and their binding proteins: Biological actions
8. Molecular and cellular aspects of the insulin-like growth factor I receptor
9. Insulin-like growth factor binding proteins in serum and other biological fluids: Regulation and functions
10. Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells
11. Castration-induced apoptosis in the rat ventral prostate is associated with increased expression of genes encoding insulin-like growth factor binding proteins 2, 3, 4 and 5
12. Insulin-like growth factor binding protein 3 mediates retinoic acid and transforming growth factor beta 2-induced growth inhibition in human breast cancer cells
13. 3 and its analog EB 1089
14. Vitamin D analogue EB1089-induced prostate regression is associated with increased gene expression of insulin-like growth factor binding proteins
15. Identification of insulin-like growth factor-binding protein-3 (IGFBP-3) fragments and IGFBP-5 proteolytic activity in human seminal plasma: A comparison of normal and vasectomized patients
16. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-β1 on programmed cell death through a p53- and IGF-independent mechanism
17. Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) is a potential tumor suppressor protein for prostate cancer
18. Association between serum insulin growth factor-I (IGF-I) and a simple sequence repeat in IGF-I gene: Implications for genetic studies of bone mineral density
19. Perplexing polymorphisms: D(i)ps, Sn(i)ps, and trips
20. Novel promoter polymorphism in insulin-like growth factor-binding protein-3: Correlation with serum levels and interaction with known regulators
21. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I, and IGF-binding protein-3
22. Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells
23. Evidence that insulin-like growth factor I and growth hormone are required for prostate gland development
24. Systemic administration of insulin-like growth factor I (IGF-I) causes growth of the rat prostate
25. Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice
26. The insulin-like growth factor axis and prostate cancer: Lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model
27. Reduction of ventral prostate weight by finasteride is associated with suppression of insulin-like growth factor I (IGF-I) and IGF-I receptor genes and with an increase in IGF binding protein 3
28. Growth hormone-releasing antagonist Mz-5-156 inhibits growth of Du-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mrna expression of insulin-like growth factor Ii in tumors
29. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor
30. Insulin-like growth factor 1 (IGF-1), IGF-1 density, and IGF-1/PSA ratio for prostate cancer detection
31. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study
32. Insulin-like growth factor 1 and prostate cancer risk: A population-based, case-control study
33. Insulin-like growth factors and prostate cancer: A population-based case-control study in China
34. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia
35. Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer
36. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: A prospective study
37. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction
38. The study of cancer risks in populations
39. Insulin-like growth factor-binding protein-1 and prostate cancer
40. Hormonal predictors of prostate cancer: A meta-analysis
41. Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen
42. Serum insulin-like growth factor-I is not a useful marker of prostate cancer
43. Correlation of preoperative plasma IGF-I levels with pathologic parameters and progression in patients undergoing radical prostatectomy
44. The significance of serum levels of insulin-like growth factor-1 in patients with prostate cancer
45. Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: The relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation
46. Dietary fat and carbohydrates are independently associated with circulating insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 concentrations in healthy adults
47. Hormones and diet: Low insulin-like growth factor-I but normal bioavailable androgens in vegan men
48. Lower prostate cancer risk in men with elevated plasma lycopene levels: Results of a prospective analysis
49. Lycopene interferes with cell cycle progression and insulin-like growth factor I signaling in mammary cancer cells
50. Silibinin up-regulates insulin-like growth factor binding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells
51. Body size and prostate cancer: A 20-year follow-up study among 135006 Swedish construction workers
52. Racial variation in insulin-like growth factor-I and binding protein-3 concentrations in middle-age men
53. Racial differences in insulin-like growth factor binding protein-3 in men at increased risk of prostate cancer
54. Bicalutamide (Casodex)-induced prostate regression involves increased expression of genes encoding insulin-like growth factor binding proteins
55. Castration-induced apoptosis of androgen-dependent shionogi carcinoma is associated with increased expression of genes encoding insulin-like growth factor-binding proteins
56. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant
57. Mechanism of antineoplastic action of somatostatin analogues
58. Can measurements of IGF-1 and IGFBP-3 improve the sensitivity of prostate-cancer screening?
59. Growth hormone (GH) replacement therapy: Cancer in adults treated with GH
60. IGFs and human cancer: Implications regarding the risk of growth hormone therapy
61. Secular trend in body height and weight of Australian children and adolescents
62. Secular trends in male adult height 1904-1996 in relation to place of residence and parent's educational level in Portugal
63. Secular changes in the growth of Toronto children during the last century
64. Cancer and insulin-like growth factor-I: A potential mechanism linking the environment with cancer risk
65. Insulin-like growth factor-I: A key regulator of human cancer risk?
66. Study suggests new way to gauge prostate cancer risk
67. Insulin-like growth factor-I and new opportunities for cancer prevention